Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

被引：11

作者：

Hamilton, E. P. ^{[1
]}

Barve, M. A. ^{[2
]}

Tolcher, A. W. ^{[3
]}

Buscema, J. ^{[4
]}

Papadopoulos, K. P. ^{[5
]}

Zarwan, C. ^{[6
]}

Anderson, C. K. ^{[7
]}

Doroshow, D. ^{[8
]}

Wang, D. ^{[9
]}

Huebner, D. ^{[10
]}

Jansen, V. M. ^{[10
]}

Jarlenski, D. ^{[10
]}

Mosher, R. ^{[10
]}

Kaufman, J. ^{[10
]}

Moore, K. N. ^{[11
]}

Richardson, D. L. ^{[11
]}

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[2] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA

[3] NEXT OncologyTM, San Antonio, TX USA

[4] Arizona Oncol Associates, Oncol, Tucson, AZ USA

[5] South Texas Accelerated Res Therapeut START, Clin Res, San Antonio, TX USA

[6] Lahey Hosp & Med Ctr, Oncol, Burlington, MA USA

[7] Willamette Valley Canc Inst, Oncol, Eugene, OR USA

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Hematol Oncol, New York, NY 10029 USA

[9] Henry Ford Hosp, Hematol Oncol, Detroit, MI 48202 USA

[10] Mersana Therapeut Inc, Clin Dev, Cambridge, MA USA

[11] Univ Oklahoma, Sarah Cannon Res Inst, Stephenson Canc Ctr, Gynecol Oncol Dept, Oklahoma City, OK USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.975

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

836P

引用

页码：S627 / S628

页数：2

共 45 条

[1] Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
Mosher, Rebecca
Poling, Laura
Qin, LiuLiang
Bodyak, Natalya
Bergstrom, Donald
[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[2] The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Bodyak, Natalya D.
Mosher, Rebecca
Yurkovetskiy, Aleksandr, V
Yin, Mao
Bu, Charlie
Conlon, Patrick R.
Demady, Damon R.
DeVit, Michael J.
Gumerov, Dmitry R.
Gurijala, Venu R.
Lee, Winnie
McGillicuddy, Dennis
Park, Peter U.
Poling, Laura L.
Protopova, Marina
Qin, LiuLiang
Stevenson, Cheri A.
Ter-Ovanesyan, Elena
Uttard, Alex
Xiao, Dongmei
Xu, Jian
Xu, Ling
Bergstrom, Donald A.
Lowinger, Timothy B.
[J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (05) : 896 - 905
[3] Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
Richardson, Debra
Hamilton, Erika
Barve, Minal
Anderson, Charles
Taylor, Sara
Lakhani, Nehal
Buscema, Joseph
Tolcher, Anthony
Zarwan, Corrine
Werner, Theresa
Hays, John
Arend, Rebecca
Edenfield, Jeffery
Putiri, Emily
Bernardo, Patricia
Burger, Robert
Matulonis, Ursula
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S48 - S48
[4] A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation
Richardson, D. L.
Hamilton, E.
Tolcher, A.
Burns, T. F.
Edenfield, W. J.
Papadopoulos, K. P.
Matulonis, U. A.
Huebner, D.
Mosher, R.
Jarlenski, D.
Pennock, G.
Cyr, M.
Ulahannan, S. V.
Moore, K. N.
[J]. GYNECOLOGIC ONCOLOGY, 2020, 159 : 52 - 52
[5] UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
Hays, John
Werner, Theresa
Lakhani, Nehal
Edenfield, Jeffrey
Buscema, Joseph
Burns, Timothy
Carrington, Cassandra
Keeton, Erika
Burger, Robert
Anderson, Charles
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
[6] Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
Lakhani, Nehal
Burns, Timothy
Barve, Minal
Edenfield, Jeffery
Hays, John
Zarwan, Corrine
Werner, Theresa
Anderson, Charles
Buscema, Joseph
Bernardo, Patricia
Keeton, Erika
Carrington, Cassandra
Burger, Robert
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S285 - S286
[7] Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
Tolcher, Anthony W.
Ulahannan, Susanna Varkey
Papadopoulos, Kyriakos P.
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Mosher, Rebecca
Fielman, Barbara
Hailman, Eric
Burris, Howard A.
Moore, Kathleen N.
Hamilton, Erika Paige
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A post-hoc analysis of a phase 1b expansion study in ovarian cancer
Monk, Bradley
Concin, Nicole
Richardson, Debra
Ray-Coquard, Isabelle
Pothuri, Bhavana
Marth, Christian
Bernardo, Patricia
Burger, Robert
Im, Ellie
Aldairy, Wassim
Coleman, Robert
Mirza, Mansoor
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S166 - S166
[9] Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
Richardson, Debra L.
Barve, Minal A.
Strauss, James Fredric
Ulahannan, Susanna Varkey
Moore, Kathleen N.
Hamilton, Erika Paige
Johnson, Melissa Lynne
Papadopoulos, Kyriakos P.
Zarwan, Corrine
Anderson, Charles K.
Buscema, Joseph
Doroshow, Deborah Blythe
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Huebner, Dirk
Jansen, Valerie Malyvanh
Mosher, Rebecca
Jarlenski, Donna
Tolcher, Anthony W.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF THE XMT-1536-1 TRIAL OF UPIFITAMAB RILSODOTIN (XMT-1536; UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-RESISTANT OVARIAN CANCER
Richardson, Debra
Perez Fidalgo, Jose Alejandro
Gonzalez-Martin, Antonio
Oaknin, Ana
Hamilton, Erika
Hays, John
Pothuri, Bhavana
Papadopoulos, Kyriakos
Taylor, Sara
Huang, Marilyn
Lee, Yeh-Chen
Krivak, Thomas
Moreno-Garcia, Victor
Calvo, Emiliano
Randall, Leslie
Starks, David
Ross, Malcom
Duska, Linda
Gao, Bo
Poka, Robert
Putiri, Emily
Barrett, Jamie
Demars, Leslie
Concin, Nicole
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241

← 1 2 3 4 5 →